A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2014
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Janssen Pharmaceutical KK
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
- 14 Dec 2012 Actual initiation date changed from Sep 2010 to Oct 2010 as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History